Odyssey Investment Partners

590 Madison Avenue
New York, NY 10022

Website: odysseyinvestment.com

Firm Size

  • Assets Under Management (AUM):$6.1 Billion
  • Number of Funds:14
  • Employees:45
  • Firm Type:Private Equity
  • Focus Areas: Services
    Healthcare


Description

Odyssey Investment Partners, LLC is a private equity firm based in New York, NY. The firm was founded in 1995 and has since established itself as a leading investor in middle-market companies. Odyssey primarily targets companies in the industrial, business services, healthcare, and aerospace sectors. With a focus on partnering with management teams to build sustainable businesses, Odyssey has a successful track record of creating value for its investors. They typically provide capital for growth, acquisitions, and recapitalizations and actively work with portfolio companies to improve performance and achieve long-term growth. Odyssey's team of experienced professionals brings deep industry knowledge and operational expertise to the table. They leverage their network and resources to support portfolio companies in strategic decision-making, operational excellence, and value creation. Reputation-wise, the firm is known for its collaborative approach, integrity, and commitment to building enduring relationships. With an exceptional investment history spanning more than two decades, Odyssey has successfully executed numerous transactions, including buyouts, carve-outs, and minority investments. They have raised several funds and manage billions of dollars in assets. Notable investments in their portfolio include Aurora Flight Sciences, Optimum Outcomes, and MagnAflux. Overall, Odyssey Investment Partners, LLC is a reputable private equity firm specializing in middle-market investments. Through its strategic approach and deep industry experience, the firm aims to generate attractive returns for its investors while supporting the growth and success of its portfolio companies.

Latest News

Powered by

May 02, 2024: Revolutionizing Patient Care: ProPharma and PBL Launch Innovative Cell & Gene Therapy Manufacturing Device


Apr 18, 2024: ProPharma Now Certified as Medidata Rave EDC Accredited Partner
  ProPharma https://www.propharmagroup.com , the world's largest Research Consulting Organization ( RCO ), the leading global provider of regulatory, clinical, and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners https://www.odysseyinvestment.com/ , today announced that it received accreditation as a CRO partner for Medidata Rave EDC . This milestone marks a significant enhancement in ProPharma's service offering and ability to develop robust, custom electronic data collection systems for clinical research studies. Joining Medidata's industry-leading partner program underscores its commitment to delivering cutting-edge, scalable global solutions throughout the development lifecycle for its Sponsors.

Apr 10, 2024: ProPharma Announces Changes to Its Executive Leadership Team


Jan 24, 2024: ProPharma Announces the Appointment of Vicki Gashwiler as Vice President of Clinical Operations, Medical Technology


Jan 04, 2024: ProPharma Unveils Prodigy: Groundbreaking Technology-Enabled Consulting Platform to Revolutionize Life Science Consulting Industry


Dec 06, 2023: ProPharma Expands into Central And Eastern Europe Through Acquisition of Clinres Farmacija


Nov 29, 2023: MERCALIS ANNOUNCES EXPANSION OF ACCESS AND ADHERENCE TECHNOLOGIES
Mercalis, an integrated life sciences commercialization partner that provides comprehensive solutions that span the entire healthcare value chain, today announced an exclusive perpetual license to a portfolio of access and adherence technologies from OptimizeRx, a health technology company focused on bringing life sciences support to patients and providers. This is Mercalis's eighth deal since entering a partnership with Odyssey Investment Partners, LLC in November 2017 .

Oct 12, 2023: ProPharma Group Recognized by Everest Group as a Major Contender in Life Sciences Operations PEAK Matrix® Assessment 2023


Sep 27, 2023: ProPharma Appoints Alena Hammond as Global Head of Clinical Operations


Sep 13, 2023: ProPharma Introduces ClinCHAT, a Solution to Unleash the Power of Real-World Evidence with Conversational AI


Aug 30, 2023: ProPharma Expands Regulatory Sciences Team in the Japan and Asia-Pacific Region with Addition of Neama Baho


Aug 15, 2023: ProPharma Recognized on the Inc. 5000 List of America's Fastest-Growing Companies